Aztreonam Patent Expiration
Aztreonam is Used for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. It was first introduced by Laboratoires Delbert
Aztreonam Patents
Given below is the list of patents protecting Aztreonam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cayston | US7208141 | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
Dec 20, 2021
(Expired) | Gilead |
| Cayston | US7214364 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec 20, 2021
(Expired) | Gilead |
| Cayston | US7427633 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec 20, 2021
(Expired) | Gilead |
| Cayston | US8399496 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec 20, 2021
(Expired) | Gilead |
Aztreonam's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Aztreonam:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
